Tellurium compounds have been described as potential leishmanicides, bearing promising leishmanicidal and antimalarial effects. Therefore, the present study investigated the pharmacological potential of the organotellurane compound RF07 through preADMET parameters, such as absorption, distribution, metabolism and excretion. After studying the pharmacokinetic properties of RF07, studies were carried out on dogs naturally infected with visceral leishmaniasis after the administration of RF07, in order to assess pathophysiological parameters. Thus, dogs were divided into 4 groups with administration of daily intraperitoneal injections for 3 weeks (containing RF07 or placebo). During the trial, hematological parameters, renal and hepatic toxicity were evaluated. Serum urea, creatinine, alkaline phosphatase, transaminases (GOT and GPT), as well as hemogram results, were evaluated before the first administration and during the second and third weeks after the start of the treatment. In dogs with VL, RF07 improved liver damage, regulated GPT levels and significantly decreased leukocyte count, promoting its regularization. These phenomena occurred at the end of the third week of treatment. The administration of RF07 promoted a significant decrease in the average levels of GOT and GPT after the third week of treatment and did not significantly alter the hematological parameters. The application of RF07 in the treatment of visceral leishmaniasis suggests that it is an alternative to the disease, since the reversal of clinical signs in dogs with VL requires the use of 0.6 mg/kg.

碲化合物已被描述为潜在的利什曼杀菌剂，具有有希望的利什曼杀菌和抗疟作用。因此，本研究通过preADMET参数（例如吸收，分布，代谢和排泄）研究了有机碲烷化合物RF07的药理潜力。在研究了RF07的药代动力学特性之后，对RF07给药后自然感染内脏利什曼病的狗进行了研究，以评估其病理生理参数。因此，将狗每天腹膜内注射3周分为4组（含有RF07或安慰剂）。在试验过程中，评估了血液学参数，肾脏和肝脏毒性。血清尿素，肌酐，碱性磷酸酶，转氨酶（GOT和GPT），在首次给药前以及治疗开始后的第二周和第三周对血脂和血脂结果进行了评估。在VL犬中，RF07改善了肝损伤，调节了GPT水平，并显着减少了白细胞计数，从而促进了其正常化。这些现象在治疗的第三周结束时发生。在治疗的第三周后，RF07的施用促进了GOT和GPT平均水平的显着降低，并且没有显着改变血液学参数。RF07在内脏利什曼病的治疗中的应用表明它是该疾病的替代方法，因为VL犬的临床体征逆转需要使用0.6 mg / kg。在第一次给药前以及治疗开始后的第二周和第三周进行评估。在VL犬中，RF07改善了肝损伤，调节了GPT水平，并显着减少了白细胞计数，从而促进了其正常化。这些现象在治疗的第三周结束时发生。在治疗的第三周后，RF07的施用促进了GOT和GPT平均水平的显着降低，并且没有显着改变血液学参数。RF07在内脏利什曼病的治疗中的应用表明它是该疾病的替代方法，因为VL犬的临床体征逆转需要使用0.6 mg / kg。在第一次给药之前以及治疗开始后的第二周和第三周进行评估。在VL犬中，RF07改善了肝损伤，调节了GPT水平，并显着减少了白细胞计数，从而促进了其正常化。这些现象在治疗的第三周结束时发生。在治疗的第三周后，RF07的施用促进了GOT和GPT平均水平的显着降低，并且没有显着改变血液学参数。RF07在内脏利什曼病的治疗中的应用表明它是该疾病的替代方法，因为VL犬的临床体征逆转需要使用0.6 mg / kg。促进其正规化。这些现象在治疗的第三周结束时发生。在治疗的第三周后，RF07的施用促进了GOT和GPT平均水平的显着降低，并且没有显着改变血液学参数。RF07在内脏利什曼病的治疗中的应用表明它是该疾病的替代方法，因为VL犬的临床体征逆转需要使用0.6 mg / kg。促进其正规化。这些现象在治疗的第三周结束时发生。在治疗的第三周后，RF07的施用促进了GOT和GPT平均水平的显着降低，并且没有显着改变血液学参数。RF07在内脏利什曼病的治疗中的应用表明它是该疾病的替代方法，因为VL犬的临床体征逆转需要使用0.6 mg / kg。